OSI Pharmaceuticals, Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301

Sept. 6, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that (OSI) Prosidion, its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics, reported positive results from a metformin drug interaction study in healthy volunteers with its dipeptidyl peptidase-IV (DP-IV) inhibitor, PSN9301... read here the OSI Pharmaceuticals' Press Release -